Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | PPARG | P37231 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | PPARA | Q07869 | 1/20 | 1.00 |
| ▸ | RORC | P51449 | 7/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | THPO | P40225 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369085 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2CYP3A4MAPK1PPARGALOX15 | |
| Hydrochloric Acid SCHEMBL7125284 | 0.99 | SMN1; SMN2 (0.97) | SMN1; SMN2CYP3A4MAPK1PPARGALOX15 | |
| SCHEMBL27886556 | 0.95 | SMN1; SMN2 (0.90) | SMN1; SMN2CYP3A4MAPK1PPARGALOX15 | |
| SCHEMBL7127082 | 0.93 | SMN1; SMN2 (0.86) | SMN1; SMN2CYP3A4MAPK1PPARGALOX15 | |
| SCHEMBL7122859 | 0.92 | MAPK1 (0.86) | SMN1; SMN2CYP3A4MAPK1PPARGALOX15 | |
| SCHEMBL7122930 | 0.90 | PPARG (0.80) | SMN1; SMN2CYP3A4MAPK1PPARGALOX15 | |
| SCHEMBL7127507 | 0.89 | PPARG (0.80) | SMN1; SMN2CYP3A4MAPK1PPARGALOX15 | |
| SCHEMBL7130609 | 0.89 | RORC (0.84) | SMN1; SMN2CYP3A4MAPK1PPARGALOX15 | |
| SCHEMBL420231 | 0.86 | RORC (1.00) | SMN1; SMN2CYP3A4MAPK1PPARGALOX15 | |
| SCHEMBL7121705 | 0.86 | RORC (0.80) | SMN1; SMN2CYP3A4MAPK1PPARGALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546382-B2 | Methods for enhancing hematopoietic progenitor cell engraftment | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-10-01 | — | — | US | claimed |
| US-20120101067-A1 | METHODS FOR ENHANCING HEMATOPOIETIC PROGENITOR CELL ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-04-26 | — | — | US | claimed |
| WO-2010121008-A2 | METHODS FOR ENHANCING HEMATOPOIETIC PROGENITOR CELL ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-10-21 | — | — | WO | claimed |
| EP-2066355-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | Braincells, Inc. (US) | 2009-06-10 | — | — | EP | claimed |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | claimed |
| WO-2008036678-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| US-20030130343-A1 | Fat accumulation-modulating compounds | ADIPOGENIX, INC. (US) | 2003-07-10 | — | — | US | claimed |
| WO-2003013516-A1 | FAT ACCUMULATION-MODULATING COMPOUNDS | ADIPOGENIX, INC. (US) | 2003-02-20 | — | — | WO | claimed |
| EP-4666856-A2 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | Corteva Agriscience LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12490741-B2 | Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto | CORTEVA AGRISCIENCE LLC (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250359552-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4653053-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4380928-B1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-3578543-B1 | COMPOSITIONS COMPRISING MOLECULES HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-2066355-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | Braincells, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008036678-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| CN-1440383-A | PPAR gamma modulators | SANKYO CO (JP) | 2003-09-03 | — | — | CN | disclosed |
| US-20030134859-A1 | PPAR-gamma modulator | SANKYO COMPANY, LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1277729-A1 | PPAR (GAMMA) MODULATORS | Sankyo Company, Limited (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | PPARG, PPARA, PPARD | SMN1; SMN2 339/4885CYP3A4 4823/4885MAPK1 1344/4885 |
| US-20030130343-A1 | Fat accumulation-modulating compounds | FABP4, LIPC, PLIN1 | SMN1; SMN2 3760/4885CYP3A4 2534/4885MAPK1 3233/4885 |
| US-20030134859-A1 | PPAR-gamma modulator | PPARG, PPARA, PPARD | SMN1; SMN2 3743/4885CYP3A4 1516/4885MAPK1 231/4885 |
| US-20250359552-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | ACHE, DDT, MLYCD | SMN1; SMN2 3645/4885CYP3A4 933/4885MAPK1 2273/4885 |
| US-12490741-B2 | Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto | ACHE, DDT, MLYCD | SMN1; SMN2 3645/4885CYP3A4 933/4885MAPK1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.